GLPG - GALAPAGOS NV

QQQ $ 468.45 $ -0.18 (-0.04 %)

DIA $ 409.66 $ 0.20 (0.05 %)

SPY $ 554.86 $ -0.13 (-0.02 %)

TLT $ 100.19 $ -0.18 (-0.17 %)

GLD $ 234.60 $ -0.04 (-0.02 %)

Previous Close

$ 29.22

Open

$ 28.97

Bid

-- x --

Ask

$ 28.93 x 200

Day's Range

$ 28.97 - $ 29.03

52 Week Range

$ 24.16 - $ 42.46

Volume

93,044

Average Volume

Market Cap

1.93B

Beta (5Y Monthly)

$ 0.84

PE Ratio (TTM)

$ 8.22

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Leerink Partners Initiates Coverage On Gal...
09/09/2024 12:52:34

Leerink Partners analyst Faisal Khurshid initiates coverage on Galapagos (NASDAQ:GLPG) with a Market Perform rating and anno...

why-tripcom-group-shares-are-trading-higher-by-around-10-here-are-20-stocks-moving-premarket

Why Trip.com Group Shares Are Trading High...
08/27/2024 09:48:21

major-investor-says-galapagos-is-undervalued-plans-to-push-on-companys-performance-and-strategic-opportunities

Major Investor Says Galapagos Is 'Underval...
08/26/2024 16:38:02

Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees sha...

galapagos-xpeng-cormedix-and-other-big-stocks-moving-higher-on-monday

Galapagos, XPeng, CorMedix And Other Big S...
08/26/2024 13:59:41

Ecor1 Capital Reported A 9.9% Stake In Gal...
08/26/2024 10:57:40

why-mira-pharmaceuticals-shares-are-trading-higher-by-around-45-here-are-20-stocks-moving-premarket

Why MIRA Pharmaceuticals Shares Are Tradin...
08/26/2024 09:58:17

$galapagos-gets-fda-nod-for-ind-application-on-phase-12-atalanta-1-study-of-cd19-car-t-therapy-glpg5101-in-refractory-non-hodgkin-lymphoma$

Galapagos Gets FDA Nod For IND Application...
08/23/2024 05:52:06

Galapagos NV announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos' Investigational New Drug (IN...

Galapagos Receives Transparency Notificati...
08/20/2024 20:05:17

Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 16 August 2024 from FMR LLC, w...

fda-approves-adaptimmune-therapeutics-engineered-cell-therapy-as-first-for-solid-tumor-and-new-therapy-for-rare-soft-tissue-cancer-in-over-a-decade

FDA Approves Adaptimmune Therapeutics' Eng...
08/02/2024 12:46:46

FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large jo...

Galapagos Q2 2024 Adj EPS $1.51 Beats $(0....
08/01/2024 20:06:43

Galapagos (NASDAQ:GLPG) reported quarterly earnings of $1.51 per share which beat the analyst consensus estimate of $(0.04) by ...

BridGene Biosciences Expands Collaboration...
08/01/2024 20:02:49

$galapagos-to-present-data-on-cd19-car-t-candidate-glpg5101-for-relapsedrefractory-non-hodgkin-lymphoma-at-eha-2024$

Galapagos To Present Data On CD19 CAR-T Ca...
06/14/2024 20:03:11

Galapagos And Adaptimmune Enter Clinical C...
05/30/2024 20:02:10

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next gener...

Galapagos And Blood Centers Of America Col...
05/15/2024 20:03:06

BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product ...

Galapagos Q1 EPS €1.40 Vs €0.40 YoY; Reven...
05/02/2024 20:37:56

Results from our continuing operationsTotal operating loss from continuing operations for the three months ended 31 March 2024 ...

Morgan Stanley Maintains Equal-Weight on G...
04/22/2024 17:23:34

Morgan Stanley analyst Judah Frommer maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and maintains $38 price target.

Galapagos Plans Clinical And Translational...
04/04/2024 20:03:43

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL...

galapagos-downgraded-pharma-firm-faces-uphill-battle-with-slow-pipeline-progress-analyst

Galapagos Downgraded, Pharma Firm Faces Up...
04/01/2024 18:37:03

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded m...

B of A Securities Downgrades Galapagos to ...
04/01/2024 11:07:37

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...

B of A Securities Downgrades Galapagos to ...
03/28/2024 10:20:03

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...